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ABSTRACT 
This study gives an understanding about the PTH mode of action as it accelerates the natural fracture 
healing process by shrinking callus size and increasing degree of mineralization of the fracture callus; 
thereby restoring intrinsic material properties. But, in human beings very few clinical research studies has 
been conducted with help of Hormonal parameters and its fluctuation during fracture healing with use of 
Ayurvedic formulation. Based on this, a random controlled study was conducted and fracture healing was 
assessed in the patients with simple and single fracture with assessment parameter hormone PTH 
(parathyroid hormone) and resulting values were statistically evaluated during fracture healing. treated 
group shows elevation pattern of serum hPTH so early initiation of bone resorption with early initiation of 
osteoblastic activity and continuous up to bone maturation so hardening of callus at fractured site may also 
quicker and this may helps to reduction in healing period or immobilization period and so early 
rehabilitation is possible.  
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INTRODUCTION
 In present days the fracture healing is assessed 
subjectively along with various objective parameters like 
radiological, histopathological, mechanical, biochemical 
and hormonal parameters. Among these radiological, 
histopathological, mechanical methods are commonly 
followed by most of the researchers in assessing fracture 
healing and the other hormonal assessment methods used 
seldom in comparison. Animal study demonstrates that 
parathyroid hormone accelerates natural fracture healing 
process in the femoral osteotomy model at Department of 
Orthopedic Surgery, Faculty of Medicine, Kagawa 
University, 1750-1 Ikenobe, Miki-cho, Kita-gun, and 
Kagawa, Japan.[1] This study gives an understanding about 
the PTH mode of action as it accelerates the natural 
fracture healing process by shrinking callus size and 
increasing degree of mineralization of the fracture callus; 
thereby restoring intrinsic material properties. But, in 
human beings very few clinical research studies has been 
conducted with help of Hormonal parameters and its 
fluctuation during fracture healing with use of Ayurvedic 
formulation. Based on this, a random controlled study was 
conducted and fracture healing was assessed in the 
patients with simple and single fracture with assessment 
parameter hormone PTH (parathyroid hormone) and 
resulting values were statistically evaluated during 
fracture healing. 
Parathyroid hormone[2] Human parathyroid hormone 
(hPTH)) is an 84 amino acid residue peptide it is a major 
physiological regulator of phosphocalcic metabolism. 
hPTH increases serum calcium concentration by its action 
on kidney (enhancing tubular ca++ reabsorption and 
phosphate excretion) and bone (stimulating osteoclastic 
activity and bone resorption). It indirectly affects intestinal 
absorption of ca++ by stimulating renal 1alpha 
hydroxylation of 25 hydroxyvitamin D. The release of PTH 
is controlled by the serum concentration of ca++. The 
measurement of intact PTH correlates best with the 
hormone production and biological activity. Low-dose 
hPTH triggers cyclic AMP-dependent protein kinase in 
some populations of bone cells bearing PTH receptors, 
which stimulates the proliferation of osteoblasts. 
 
Cissus quadrangularis & Fracture Healing 
Studies on fracture healing suggest that this 
unidentified anabolic steroid may act on estrogenic 
receptors of the bone. Efficacy of Cissus quadrangularis on 
early ossification and remodeling of bones have been 
reported and it has been observed that Cissus 
quadrangularis acts by stimulation of metabolism and 
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increased uptake of the minerals calcium, sulpher and 
strontium by the osteoblasts in fracture healing.[3] Cissus 
quadrangularis is found to contain vitamins and steroids, 
which are found to have specific effect on bone fracture 
healing. The anabolic steroidal principles from Cissus 
quadrangularis showed a marked influence in the rate of 
fracture healing by influencing early regeneration of all 
connective tissues involved in the healing and quicker 
mineralization of callus. 
Purpose: Though, the drug Cicccus Quadrangularis is 
being used in fracture healing since days of Samhitas. The 
action of drug in accelerating the process of bone healing 
was not explored on objective evidences. Hence, the study 
was undertaken with the purpose, ‘to explore the 
physiological impact of Cicccus Quadrangularis and 
ultimately on the process of bone healing in terms of 
parathyroid hormone fluctuation’ 
METHODOLOGY 
Aim: To evaluate the effective remedial therapy for 
acceleration of fracture healing so as to Rehabilitate the 
individual as early as possible.  
Objective 
To correlate the serial values of parathyroid hormones 
during process of fracture healing.  
Study design 
Study Type  : Interventional 
Purpose  : Treatment 
Control   : controlled 
Timing   : Prospective 
No. of Groups  : Two 
Sample Size  : 40 in each group (Total=40x2 i.e. 80) 
 
Inclusion Criteria 
1. Patients of single bone fracture with good general 
condition. 
2. Males or non pregnant females aged 12 to 70 yrs.  
3. Able to communicate adequately with the 
investigator and to comply with the requirements for 
the entire study. 
4. Capable of and freely willing to provide written 
informed consent prior to participating in the study.  
Exclusion Criteria 
1. Patients of systemic disorders like DM, PTB, 
malignancy 
2. Patients of thyroid dysfunction history 
3. Patients of calcium disorder  
4. Patients of open fracture and fracture with 
dislocation & who requires acute medical care and 
surgical interventation. 
5. Patients below 12yrs and above 70yrs. 
6. Immunocompressive patients 
7. Highly Displaced fracture which needs anesthesia to 
reduce. 
8. Pregnant / Lactating women.  
9. Patient on steroids, oral contraceptive pills or 
estrogen replacement therapy. 
10. Alcoholics and/or drug abusers. 
11. Patients suffering from major systemic illness 
necessitating long term drug treatment 
(Rheumatoid arthritis, Psycho-Neuro-Endocrinal 
disorders, etc.) 
12. H/o hypersensitivity to any of the trial drugs or 
their ingredients. 
13. Patients who have completed participation in any 
other clinical trial during the past six (06) months. 
14. Any other condition which the Investigator thinks 
may jeopardize the study. 
Drug interventions 
For Group A (Treated group) 
1.Drug - Asthishrunkhala churna  
2. Dose – 10 gm per day in three divide doses 
3. Route of administration – orally 
4. Vehicle – Luke warm water 
5. Duration- 30 days. 
For Group B (controlled Group) 
1.Drug-Starch (placebo therapy)  
2.Dose – 500mg  
3. Route of administration – orally,  
4. Vehicle – Luke warm water  
5. Duration- 30 days.  
General management of fracture 
 It includes Immobilization of the part i.e.post cast 
and POP. Post cast on day 1st, POP on 7th day. For trial 
group (A) Anti-inflammatory analgesic drugs are avoided 
because drug Ciccus qudrangularis has anti-inflammatory 
analgesic property. Patients in Group-A who required 
medication for further complications they are excluded 
from study with proper advice and care. Patients of 
Group-B for pain plain paracetomol/Diclofenac sodium is 
given if needs and separate documentation was 
maintained. Patients were advised to follow-up on Day 07, 
21& day 31 to assess parameters.  
Assessment parameter (Objective) 
1. Hormone – parathyroid hormone is assessed on Day 
1st, 7th, 21st& 31st day. 
Methods of assessment 
Prior to selection (Screening) 
1. Informed Consent /Assent 
2. Eligibility evaluation 
3. Laboratory investigations 
During Selection (Baseline) 
1. General information- (Personal Identification and 
Demographic profile) 
2. Medical history, General Physical and Systemic 
examination 
3. Clinical Assessment by fracture Symptoms and 
radiograph. 
4. Issue of drugs and drug compliance report form 
5. Instructions to come on next visit 
During Treatment i.e. on 7th, 21st, 31st 
1. Assessing drug compliance 
2. Physical examination 
3. Laboratory investigations (Serum PTH) 
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4. Issue of drugs and drug compliance report form 
Statistical analysis 
 Hormone parameter presented as mean ± SD. 
Categorical variables were expressed in actual numbers 
and percentage. One way repeated measure ANOVA test 
was performed to compare the Serum parathyroid 
hormone at different points in each group. Changes in 
these variables at different time point between two groups 
were compared by wilcoxan rank sum test (Mann–
Whitney test). STATA version 10.0 was used for statistical 
analysis. 
Data Management: A case report form (CRF) for each 
patient in trial is prepared to note down all clinical 
observations. The data is handled in a way to maintain 
confidentially and ensure accuracy. Efforts were made to 
maintain error free records. 
Ethics: Institutional Ethics Committee: after ethical 
approval for study from IEC work was initiated and the 
final study report is also presented before the Institutional 
Ethics Committee(s) for approval. All amendments 
suggested by EC(s) are implemented and letter of pre & 
final approval of institutional ethical committee enclosed 
in annexure.  
OBSERVATION, RESULTS & DISCUSSION 
Total 96 patients were screened for study. Out of 
them 12 patients are excluded with proper referral as they 
did not fit in inclusion criteria, whereas 04 patients are 
withdrawn from study due to protocol voidance with 
irregular follow-up. They were advised for alternative 
treatment. 80 patients were enrolled and taken-in for the 
trial assessment in the study. They were divided into two 
groups with simple random allocation method, Group A 
(Treated Group)- treated with Asthishrunkhala capsule 
orally. Group B- (Control group) treated with placebo 
Starch capsule. Observations were made during and after 
the treatment, to find out the fracture healing acceleration 
property of drug Ciccus quadrangularis in terms of Serum 
parathyroid fluctuation. 
 The observational details regarding the incidence 
factors pursue as follows: Out of the 80 patients, maximum 
18 (22.5%) patients were in 31-40 yrs age Group. 
thereafter 16 (20%) patients in age Group 41-50 yrs and 
patients in age Group 51-60 yrs are also 16 (20%). patients 
are in above 60 years age Group were 09 (11.25%) and 
patients were in 21-30 years age Group were11 (13.75%) 
and 10 (12.5 %) patients were in 12-20 years age Group. 
According to the observations noted- it is evident that a 
maximum patients inflicted by fractures were seen in 31-
40 years age group and the most common cause is the 
vehicular accident and second cause is fall which is 
common in aged group. This observation correlates the 
international prevalence of fracture and musculoskeletal 
injuries.[4] 
Regarding the incidence in genders, Out of 80 
patients, 46 (57.5 %0 patients were male & 34 (42.5%) 
patients are female. Male: Female ratio in the study was 
found out to be 60:50 the ratio regarding the incidence of 
fracture in between the sexes is found to be relatively 
insignificant. According to observation done regarding 
occupation of patients- it was found that Out of 80 patients 
under study 13 (16.25 %) patients were working in 
private sector. 04 (5 %) patients were working in govt. 
sector.11 (13.75%) patients were working in own 
business. 05 (6.25% patients were labors by occupation. 
14 (17.5%) patients were taking education. 06 (7.5%) 
patients are retired & 27 (33.75%) patients are Housewife 
by occupation Thus, it can be said that most sufferers are 
those who are engaged in daily outdoor activities. 
Regarding the bone being involved in the fracture, it was 
observed that amongst the 80 patients under the trial 
study- a maximum Numbers of 17 patients (21.25 %) were 
inflicted with fracture of the phalanx followed by fractures 
of radius – 16 in number (20 %), 05 patients (6.25 %) 
were inflicted with fracture of the Humerus bone, 09 
patients (11.25%) were inflicted with fracture of the 
Metatarsals, 08 patients (10 %) were inflicted with 
fracture of the Metacarpals, patients were inflicted with 
fracture of the Tibia are 7 in number i.e. 8.75%, Ulna – 5 in 
number (6.25%), Fibula – 2 in number (2.5 %), Calcaneum 
-2 in number (2.5 %), patella 01 in number (1.25%), 
Scaphoid -1 in number (1.25 %). ribs 04 in number (5 %), 
Clavicle 03 in numbers (3.75%). So, it is observed that 
most patients suffered from injuries of the forearm; which 
are prone to be injured in a trauma, whilst trying to 
support body against the fall.  
 Hormone PTH (parathyroid hormone) activity 
during fracture healing were analyzed and evaluated in 
both groups, serum analysis was performed as per the 
standard procedure on 1st day (baseline), 7th, 21st and 
31st day. Kits used were DIA source hPTH- ELISA kit 
Manufactured by –DIA source immunoassay S.A. Rue du 
bosquet, 2, B-1348 Louvain-la-neuve, Belgium for PTH 
analysis.  
Table 1. Shows effect on Serum hPTH at different time points 
Group Baseline Day 7 Day 21 Day 31 
A 26.78 ±9.06 29.30 ±9.44 51.60± 9.28 34.90± 7.43 
B 30.78± 7.51 37.15 ±14.57 32.95± 8.95 29.20 ±7.47 
Table 2: Comparison of Mean Serum Parathyroid Hormone at different time point in each group (Repeated 
measure ANOVA) 
   Multiple comparison 
 F-value p-value Baseline vs Day 7 Baseline vs Day 21 Day 21 vs Day31 
Group A 98.89 <0.0001, HS p>0.05, NS <0.001, HS <0.001, HS 
Group B 6.693 <0.0001, HS <0.001, HS >0.05, NS >0.05, HS 
The data obtained during the study were subjected 
to statistics analysis by repeated measure ANOVA test and 
wilcoxon Rank sum test it reveals that at different time 
points mean serum hPTH in Group A (Treated Group) was 
26.78 ±9.06, 29.30 ±9.44, 51.60± 9.28 & it was 34.90± 7.43 
at baseline, 7th, 21st and 31st Day respectively. Mean Serum 
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hPTH in Group B (Control Group) was 30.78± 7.51, 37.15 
±14.57, 32.95± 8.95 and 29.20 ±7.47 at baseline, 7th, 21st 
and 31st Day respectively. 
On comparison of Mean Serum Parathyroid 
Hormone at different time point in each Group by 
Repeated measure ANOVA test it was observed that In 
Group A serum PTH was significantly different at different 
time points (f- = 98.89, P> 0.0001) no significant change in 
serum PTH was observed at day 7th from baseline (P>0.05) 
but it was significantly increased on day 21st (p<0.001) 
and also at day 31st (P<0.001) which is highly significant. 
In Group B Serum hPTH level was significantly increased 
at day 7th (p<0.001,HS) but no significant change was 
noted at day 21st (p>0.05, NS) and day 31st (p>0.05,NS).  
 Comparison of change in serum parathyroid 
Hormone at day 7th, 21st and 31st Day from baseline 
between 2 Groups by wilcoxon Rank sum test shows Mean 
serum parathyroid Hormone on day 7th in Group A was -
2.52± 11.95 and -6.37 ±12.03 in Group B. No significant 
difference is found between two groups. (p-value is 0.155). 
While mean change in serum parathyroid Hormone on day 
21st from baseline in Group A was -24.82± 9.23 and -2.17± 
6.18 in Group B. Sr. PTH was significantly increased in 
group A as compared to group B (p-value is <0.0001,HS). 
On day 31st mean change in serum parathyroid Hormone 
in Group A was -8.12± 9.22 and 1.57± 4.77 in Group B. Sr. 
PTH was significantly increased in group A as compared to 
group B (p-value is <0.0001,HS). 
Above analysis shows that serum PTH hormone in 
group A was significantly elevated on 21st and 31st day 
when compared to baseline and 7th day But shows regular 
increasing pattern up to day 21st and from day 31st it start 
to lowering. Such pattern was not found in control group 
in this group hPTH elevated only on day 7th and further it 
remains at insignificant level up to day 31st. This shows 
significant differences in Means of group A than group B. It 
denotes drug Ciccus quadrangularis has property to 
fluctuate serum PTH and also suggests that it may early 
initiate and continuously stimulates osteoblastic activity 
during fracture healing period hence early bone healing 
and mineralization (callus hardening) may possible. This 
activity helps to reduce bone maturation period and so 
reduces the immobilization period and ultimately early 
rehabilitation can possible. 
 
 
This hPTH fluctuation is because of only drug 
Ciccus Quadrangularis property and reason for it is that 
this fluctuation pattern is seen in only group A. This may 
be due to Cissus quadrangulari s causes less amount of 
tissue reaction in the fractured region leading to optimum 
decalcification in the early stage with minimum of callus 
formation. Hence deposition of calcium is just enough to 
join the two broken segments of bone so that it’s 
remodeling takes much faster in the treated group as 
compared with controls. Cissus quadrangularis may builds 
up the chemical composition of the fractured bone namely 
its mucopolysaccharides, collagen, calcium, phosphorus 
and others as well as its functional efficiency. Early 
completion of calcification process and earlier remodeling 
phenomenon may lead to early recovery of patients. 
CONCLUSIONS 
1. In spite of lack of use of herbal remedies for fracture 
lot of references regarding drugs which may act on 
facture healing and its acceleration were available in 
Ayurvedic texts. 
2. Cissus quadrangularis is a pharmacological agent for 
acceleration of bone healing. 
3. Cissus quadrangularis treated group shows elevation 
pattern of serum hPTH, early initiation of bone 
resorption with early initiation of osteoblastic activity 
and continuous up to bone maturation so hardening of 
callus at fractured site may also quicker and this may 
helps to reduction in healing period or immobilization 
period and so early rehabilitation is possible.  
4. Drug Cissus quadrangularis accelerates bone fracture 
healing, can be easily prepared and can be safely 
administered orally without any serious or adverse 
effects.  
Future Perspectives  
1. Assessment with PTH Hormone alone is still 
debatable. These results can be strengthened by 
involving other assessment parameters like and 
biochemical parameters calcium and phosphorus, 
bone matrix density, Computed tomography and 
microangiography (to know vascularisation at 
fractured site). 
2. By increasing sample size, number of weekly follow -
ups up to 8thweek, and including other assessment 
parameters, further research work is recommended at 
higher centre having sufficient attendance of fracture 
patients so that it may be helpful to draw the accurate 
conclusion in establishing the useful and an effective 
approach in the management of Bone fractures. 
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3. The Accuracy of results may be achieved by 
conducting Multicentre studies.  
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